Literature DB >> 22116107

Hemorrhagic risk of recent silent cerebral infarct on prethrombolysis MR imaging in acute stroke.

N Gaillard1, C Schmidt, V Costalat, J P Bousquet, C Heroum, D Milhaud, A Bonafe, C Arquizan.   

Abstract

BACKGROUND AND
PURPOSE: EIH is a rare complication after thrombolysis in patients with acute stroke, occurring in brain regions without visible ischemic change on pretreatment imaging. RSCIs can be detected by multimodal MR imaging and might be associated with an increased risk of HT postthrombolysis, related to BBBD. We aimed to assess the incidence of RSCI on pretreatment MR imaging and the subsequent risk of HT within RSCI areas on follow-up CT performed <36 hours after rtPA administration and on additional cerebral imaging before patient discharge.
MATERIALS AND METHODS: Pretreatment MR imaging was retrospectively analyzed from consecutive patients with stroke who received intravenous or intra-arterial rtPA for 2 years. RSCI was defined on MR imaging as a parenchymal area markedly hyperintense on FLAIR, different from the hyperacute infarct, and mildly-to-markedly hyperintense on DWI or enhanced on postgadolinium T1WI imaging.
RESULTS: Eighty-six patients with a median age of 66 years and a median NIHSS score on admission of 15 were studied; 66.3% received rtPA intravenously. The presence of RSCI was identified in 10 patients (11.6%) and was associated with large-vessel-disease etiology (40% versus 5.3%, P < .001) on univariate analysis. No HT was identified within the RSCI areas on any follow-up cerebral imaging.
CONCLUSIONS: These preliminary results require validation but suggest that small RSCIs are rather frequent and might not pose a higher risk of postthrombolysis HT.

Entities:  

Mesh:

Year:  2011        PMID: 22116107      PMCID: PMC7964816          DOI: 10.3174/ajnr.A2768

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  28 in total

1.  Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.

Authors:  A Furlan; R Higashida; L Wechsler; M Gent; H Rowley; C Kase; M Pessin; A Ahuja; F Callahan; W M Clark; F Silver; F Rivera
Journal:  JAMA       Date:  1999-12-01       Impact factor: 56.272

Review 2.  Classification and pathogenesis of cerebral hemorrhages after thrombolysis in ischemic stroke.

Authors:  Paul Trouillas; Rüdiger von Kummer
Journal:  Stroke       Date:  2006-01-05       Impact factor: 7.914

3.  Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia: MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours.

Authors:  Götz Thomalla; Jan Sobesky; Martin Köhrmann; Jochen B Fiebach; Jens Fiehler; Olivier Zaro Weber; Anna Kruetzelmann; Thomas Kucinski; Michael Rosenkranz; Joachim Röther; Peter D Schellinger
Journal:  Stroke       Date:  2007-01-04       Impact factor: 7.914

4.  Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparison.

Authors:  Julio A Chalela; Chelsea S Kidwell; Lauren M Nentwich; Marie Luby; John A Butman; Andrew M Demchuk; Michael D Hill; Nicholas Patronas; Lawrence Latour; Steven Warach
Journal:  Lancet       Date:  2007-01-27       Impact factor: 79.321

5.  Clinical and imaging predictors of intracerebral haemorrhage in stroke patients treated with intravenous tissue plasminogen activator.

Authors:  L Derex; M Hermier; P Adeleine; J-B Pialat; M Wiart; Y Berthezène; F Philippeau; J Honnorat; J-C Froment; P Trouillas; N Nighoghossian
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-01       Impact factor: 10.154

6.  Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey.

Authors:  David Tanne; Scott E Kasner; Andrew M Demchuk; Nira Koren-Morag; Sandra Hanson; Martin Grond; Steven R Levine
Journal:  Circulation       Date:  2002-04-09       Impact factor: 29.690

7.  Yield of diffusion-weighted MRI for detection of potentially relevant findings in stroke patients.

Authors:  G W Albers; M G Lansberg; A M Norbash; D C Tong; M W O'Brien; A R Woolfenden; M P Marks; M E Moseley
Journal:  Neurology       Date:  2000-04-25       Impact factor: 9.910

8.  Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: the Thrombolysis in Myocardial Infarction (TIMI) II Pilot and Randomized Clinical Trial combined experience.

Authors:  M A Sloan; T R Price; C K Petito; A M Randall; R E Solomon; M L Terrin; J Gore; D Collen; N Kleiman; F Feit
Journal:  Neurology       Date:  1995-04       Impact factor: 9.910

9.  MRI-based and CT-based thrombolytic therapy in acute stroke within and beyond established time windows: an analysis of 1210 patients.

Authors:  Peter D Schellinger; Götz Thomalla; Jens Fiehler; Martin Köhrmann; Carlos A Molina; Tobias Neumann-Haefelin; Marc Ribo; Oliver C Singer; Olivier Zaro-Weber; Jan Sobesky
Journal:  Stroke       Date:  2007-08-16       Impact factor: 7.914

10.  Magnetic resonance imaging of cerebral infarction: time course of Gd-DTPA enhancement and CT comparison.

Authors:  S Imakita; T Nishimura; N Yamada; H Naito; M Takamiya; Y Yamada; J Minamikawa; H Kikuchi; M Nakamura; T Sawada
Journal:  Neuroradiology       Date:  1988       Impact factor: 2.804

View more
  1 in total

1.  Tirofiban combined with urokinase selective intra-arterial thrombolysis for the treatment of middle cerebral artery occlusion.

Authors:  Lei Feng; Jun Liu; Yunzhen Liu; Jian Chen; Chunhai Su; Chuanfeng Lv; Yuzhen Wei
Journal:  Exp Ther Med       Date:  2016-01-14       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.